Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

TARRYTOWN, N.Y., Oct. 27 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced it has received marketing authorization in the European Union for rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older. Marketing authorization for rilonacept was granted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) under exceptional circumstances.

"Rilonacept, which is known as ARCALYST® in the United States, has been prescribed to treat the majority of patients documented to have been treated for CAPS symptoms to date in the U.S. ARCALYST is the only treatment for CAPS in the U.S. that has demonstrated a significant improvement in CAPS symptoms as reported by patients in a pivotal clinical program and is approved for self-administration at home," said Robert Terifay, Senior Vice President, Commercial at Regeneron. "Currently, rilonacept is available to patients in the European Union through their prescribers on a named-patient or individualized case review basis. We are evaluating our broader commercialization options for this very small, ultra-orphan patient population, which is dispersed across Europe."

CAPS include a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can be triggered at any time by exposure to cooling temperatures, stress, exercise, or other unknown stimuli. Rilonacept is a targeted inhibitor of interleukin-1 (IL-1), the key driver of inflammation in CAPS
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 26, 2014 "Ischemic ... H2, 2014" provides data on the Ischemic Stroke ... provides elemental information and data relating to the ... , View full global Ischemic Stroke Research Report ... an overview of the trial numbers and their ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Lawrence Livermore ... to Thomson Reuters list of " The World's Most ... part of the 3,000 researchers who were identified by ... recognize those who published the highest-impact work (2002-2012 and ... papers on combustion modeling . , "This recognition ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), ... , today announced that it will release its unaudited ... after market close on Thursday, August 14, 2014 EDT. The ... opening on Friday, August 15, 2014, at 8:00 a.m. EDT ... to review the Company,s financial results and provide an update ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... SAN DIEGO, Aug. 25 NexBio, Inc. announced today ... Human Lung Tissues" in the September, 2009 issue of the ... DAS181 (Fludase ((R)) ) is an investigational drug ... (e.g. Tamiflu ((R)) ), which target the virus, DAS181 works ...
... 25 Peptimmune, Inc., a privately held biotechnology company, ... the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in ... is a novel peptide copolymer for the treatment of ... The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, ...
... - Medicago Inc. (TSX-V: MDG) a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... from Health Canada to commence a Phase I ... vaccine ("H5N1 vaccine"). Enrollment of volunteers is now ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... have found that targeting a molecule in blood vessels ... research published in Nature today (Sunday)., The ... University of London, have found that a molecule, called ... itself after chemotherapy or radiotherapy, which kill cancer cells ... blood vessels that grew in melanoma or lung cancer ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... the Pediatric Study of Hepatitis C (PEDS-C) trial reveals ... C (HCV) display significant changes in height, weight, body ... the August issue of Hepatology , a journal ... Diseases, indicate that most growth-related side effects are reversible ...
... Clemson University researchers are teaming up with Coastal ... of sensors along the Savannah River to gather data ... will collect and transmit real-time information about the quality ... Intelligent River project leaders Gene Eidson, director of Clemson,s ...
... Lab on a chip (LOC) devicesmicrochip-size systems that can ... from a few microliters (millionth of a liter) to ... to one day revolutionize how laboratory tasks such as ... a recent paper* from the National Institute of Standards ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2NIST focuses on testing standards to support lab on a chip commercialization 2
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... provides a simple and efficient means for ... lture using annexin V magnetic beads (MagBeads). ... protein with high affinity for phosphatidylseri ... simple and efficient means for isolation of ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: